Corporate Overview

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, Sustol™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its Sustol New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration in mid-2014.


 Stock Quote
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.45 (4.01%)
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Calendar of Events
April 2014?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
52 Week High
Recent NewsMore >>
03/31/14Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL™
Study will evaluate the prevention of delayed-onset chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 31, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company’s lead product candidate for the prevention of chemotherapy-induced nausea an... 
Printer Friendly Version
03/05/14Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (HRTX), a specialty pharmaceutical company, today reported fourth quarter and full year 2013 financial results and highlighted recent corporate progress. “In the last 12 months, we transformed ourselves into Heron Therapeutics and made important advancements to position Heron for success in 2014,” said Barry D. Quart, PharmD, Chief Executive Officer of Heron Therapeutics. “In 2013, we brought in a fresh and highly seasoned mana... 
Printer Friendly Version
01/27/14Heron Therapeutics Provides Update on Sustol Resubmission
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company's timeline for the resubmission of the new drug application (NDA) for Sustol® to the U.S. Food and Drug Administration (FDA), the Company's product candidate for chemotherapy-induced nausea and vomiting (CINV). "Subject to the FDA's review and approval of the Sustol NDA, we project being in a position to launch Sust... 
Printer Friendly Version
01/23/14Heron Therapeutics Announces Relisting on NASDAQ
January 23, 2014 08:00 AM Eastern Standard Time REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc., OTCBB: APPAD), a specialty pharmaceutical company, today announced that the Company’s common stock has been relisted on the NASDAQ Capital Market. The Company’s shares will trade under the symbol “HRTX” on the NASDAQ Capital Market when the market opens today, Thursday, January 23, 2014. “We ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.